# PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer

> **NCT02910882** · PHASE2 · TERMINATED · sponsor: **Scripps Health** · enrollment: 4 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma Non-resectable

## Interventions

- **DRUG:** PEGylated Recombinant Human Hyaluronidase (PEGPH20)
- **DRUG:** Gemcitabine
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT02910882
- **Lead sponsor:** Scripps Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-03
- **Primary completion:** 2018-08-31
- **Final completion:** 2018-08-31
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Safety
- **Last updated:** 2019-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02910882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02910882, "PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02910882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*